Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
27.78
+0.30 (1.11%)
At close: Dec 5, 2025, 4:00 PM EST
27.99
+0.21 (0.77%)
After-hours: Dec 5, 2025, 7:26 PM EST
Mersana Therapeutics Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Mersana Therapeutics stock ranges from a low of $30 to a high of $30.75. The average analyst price target of $30.38 forecasts a 9.38% increase in the stock price over the next year.
Price Target: $30.38 (+9.38%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Mersana Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 14, 2025 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $36 → $31 | Strong Buy → Hold | Downgrades | $36 → $31 | +10.71% | Nov 13, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 13, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $250 → $36 | Strong Buy | Maintains | $250 → $36 | +29.61% | Aug 14, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $125 → $30 | Strong Buy | Maintains | $125 → $30 | +8.01% | Aug 14, 2025 |
Financial Forecast
Revenue This Year
23.76M
from 40.50M
Decreased by -41.32%
Revenue Next Year
20.89M
from 23.76M
Decreased by -12.07%
EPS This Year
-8.50
from -14.12
EPS Next Year
-9.84
from -8.50
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.8M | 44.9M | ||||
| Avg | 23.8M | 20.9M | ||||
| Low | 14.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -6.7% | 89.1% | ||||
| Avg | -41.3% | -12.1% | ||||
| Low | -63.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.87 | -0.75 | |
| Avg | -8.50 | -9.84 | |
| Low | -14.90 | -16.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.